Goserelin Acetate Extended-release Microspheres LY01005 clinical trials
Also written LY01005.
How each study uses Goserelin Acetate Extended-release Microspheres LY01005 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Goserelin Acetate Extended-release Microspheres LY01005 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Luye Pharma Group Ltd. (5) · The First Affiliated Hospital of Xiamen University (1)
Studies
Open first, then newest update. How each study uses Goserelin Acetate Extended-release Microspheres LY01005 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate CancerRecruitingPhase 2The First Affiliated Hospital of Xiamen UniversityNCT06385847Written as LY01005
- Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mgNot yet recruitingPhase 1Luye Pharma Group Ltd.NCT05856630Written as Goserelin Acetate Sustained-Release Microspheres for Injection
- Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®CompletedPhase 1Luye Pharma Group Ltd.NCT05140512Written as LY01005
- Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®CompletedPhase 3Luye Pharma Group Ltd.NCT05110170Written as LY01005
- Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®CompletedPhase 3Luye Pharma Group Ltd.NCT04563936Written as LY01005 3.6 mg
- A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate CancerCompletedPhase 1Luye Pharma Group Ltd.NCT03450109Written as LY01005